



ADDING EVIDENCE-BASED THERAPIES TO HOSPITAL FORMULARY

TIP SHEET



1



Build the Case

- Define the clinical need and target population
- Review supporting evidence (see reverse side)
- Review gaps in care

2



Identify Champions

- Physician Champion
- Pharmacy Champion
- Leadership Support

3



Engage Stakeholders

- Pharmacy leadership
- Heart Failure Team
- Hospitalists
- Quality Improvement Team

4



Secure Approval

- Submit formulary request
- Prepare evidence summary
- Present to P&T Committee
- Address questions and concerns

5



Implement the Therapy

- Eligibility criteria/prescribing guidance
- EHR Tools/Templates/Order Sets
- Healthcare Professional education
- Review Get With The Guidelines-Heart Failure data

EVIDENCE MATTERS, SEE THE DATA

Scan to explore the clinical trials and published evidence supporting these formulary strategies.



Chronic Kidney Disease Type 2 Diabetes

- FIDELIO-DKD: Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med.* 2020;383(23):2219-2229. [NEJM. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes](#)
- FIGARO-DKD: Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med.* 2021;385(24):2252-2263. [Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes](#)
- FIDELITY: Agarwal R, Filippatos G, Pitt B, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Joint Analysis of FIDELIO-DKD and FIGARO-DKD. *Diabetes Care.* 2022;45(12):2991-3001. [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis | Diabetes Care | American Diabetes Association](#)
- INFINITY: Neuen BL, Heerspink HJL, Perkovic V, et al. Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY). *Lancet* 2026; 407(10546):2375-2386. [Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis \(INFINITY\) - The Lancet](#)

Chronic Kidney Disease without Type 2 Diabetes

- FIND-CKD: Neuen BL, Perkovic V, Agarwal R, et al. Finerenone in patients with chronic kidney disease due to glomerular diseases. *JAMA.* 336(3): 224-235. <https://jamanetwork.com/journals/jama/article-abstract/2850124>
- FINE-ONE: Hiddo JL, Bikenfeld AL, Cherney DZI, et al. Finerenone in type 1 diabetes and chronic kidney disease. *NEJM.* 2026; 394:947-957. [Finerenone in Type 1 Diabetes and Chronic Kidney Disease | New England Journal of Medicine](#)

Heart Failure with Preserved Ejection Fraction: Efficacy and Tolerability

- FINEARTS-HF: Solomon SD, Vaduganathan M, Claggett BL, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med.* 2024;391(12):1075-1085. [Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction | New England Journal of Medicine](#)
- FINE-HEART Pooled Analysis: Ruppert M, Vaduganathan M, Claggett BL, et al. Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis. 2026. *European Heart Journal*, ehag522, <https://doi.org/10.1093/eurheartj/ehag522>.
- Ostrominski JW, Filippato G, Claggett BL, et al. Efficacy and safety of finerenone in heart failure with preserved ejection fraction: A FINE-HEART Analysis. *JACC: Heart Failure.* 2025; 13(8): doi.org/10.1016/j.jchf.2025.03.041. [Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART Analysis - ScienceDirect](#)
- Butt JH, Jhund PS, Henderson AD, et al. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. *Lancet Diabetes Endocrinol.* 2025; 13(2): 107-118. [Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial - PubMed](#)
- Pabon MA, Filippatos G, Claggett BL, et al. JACC. 2025; 85: 1649-1660. Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: The FINE-HEART Pooled Analysis. *JACC.* 2025; 85(17): 1649-1660. [Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis - PubMed](#)
- Matsumoto S, Henderson A, Jhund PS, et al. Finerenone and atrial fibrillation in heart failure: a secondary analysis of the finearts-hf randomized clinical trial. *JAMA Cardiol.* 2025; 10: 696-707. [Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial | Trials | JAMA Cardiology | JAMA Network](#)
- Vaduganathan M, Filippatos G, Claggett BL, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. *Nat Med.* 2024; 30: 3758-3764. [Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes | Nature Medicine](#)
- ARTS Trial: Pitt B, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. *European Heart Journal.* 2013; 34: 2453-2463. [Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial | European Heart Journal | Oxford Academic](#)
- Chimura M, Jhund PS, Henderson AD, et al. Efficacy and tolerability of finerenone according to the use and dosage of diuretics. *JAMA Cardiol.* 2025; 10: 59-70. [Efficacy and Tolerability of Finerenone According to the Use and Dosage of Diuretics: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial | Trials | JAMA Cardiology | JAMA Network](#)
- Vardeny O, Vaduganathan M, Blaggett BL, et al. Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction. *JAMA Cardiol.* 2025; 10: 42-48. [Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction | Trials | JAMA Cardiology | JAMA Network](#)

GDMT Use Before and After Hospitalization for Heart Failure

- EMPACE Study: Greene SJ, Adam A, Schmedt N, et al. Contemporary guideline-directed medical therapy for heart failure in the united states: The EMPACE Study. 2026; 15(6): <https://doi.org/10.1161/JAHA.125.044785>
- Docherty et al, Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. *Circulation.* 2025 Jan 7;151(1):45-58. doi: 10.1161/CIRCULATION-NAHA.124.072011. Epub 2024 Sep 29. PMID: 39342512; PMCID: PMC11670913. [Effects of Finerenone on Readmissions for Heart Failure: Insights From the FINEARTS-HF Trial - ScienceDirect](#)
[Time to Significant Benefit of Finerenone in Patients With Heart Failure | JACC](#)